Jason Bednar
Stock Analyst at Piper Sandler
(2.01)
# 3,087
Out of 5,008 analysts
183
Total ratings
35.25%
Success rate
-5.87%
Average return
Main Sectors:
Stocks Rated by Jason Bednar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ICUI ICU Medical | Maintains: Overweight | $145 → $153 | $119.99 | +27.51% | 2 | Sep 10, 2025 | |
| COO The Cooper Companies | Maintains: Overweight | $105 → $83 | $69.69 | +19.10% | 14 | Aug 28, 2025 | |
| SOLV Solventum | Maintains: Overweight | $87 → $94 | $73.34 | +28.18% | 7 | Aug 8, 2025 | |
| BDX Becton, Dickinson and Company | Maintains: Neutral | $185 → $200 | $193.30 | +3.47% | 10 | Aug 8, 2025 | |
| MASI Masimo | Maintains: Overweight | $200 → $210 | $150.81 | +39.25% | 16 | Aug 6, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $17 → $19 | $20.47 | -7.18% | 13 | Aug 1, 2025 | |
| MMSI Merit Medical Systems | Maintains: Overweight | $110 → $105 | $83.18 | +26.23% | 13 | Jul 31, 2025 | |
| ALGN Align Technology | Maintains: Overweight | $250 → $190 | $130.63 | +45.45% | 31 | Jul 31, 2025 | |
| LUNG Pulmonx | Downgrades: Neutral | $9 → $2.5 | $1.74 | +43.68% | 12 | Jul 31, 2025 | |
| NVCR NovoCure | Reiterates: Overweight | $34 | $14.25 | +138.60% | 11 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4.5 → $3.5 | $4.00 | -12.50% | 7 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $16 | $12.45 | +28.51% | 8 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $77 | $65.77 | +17.07% | 7 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $13 | $16.15 | -19.50% | 2 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4.5 | $2.22 | +102.70% | 3 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $260 → $265 | $242.84 | +9.13% | 9 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $6 | $4.70 | +27.80% | 5 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $4.12 | +69.90% | 5 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $20 | $2.41 | +729.88% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $310 → $372 | $442.94 | -16.02% | 4 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $95 | $74.96 | +26.73% | 1 | Apr 19, 2023 |
ICU Medical
Sep 10, 2025
Maintains: Overweight
Price Target: $145 → $153
Current: $119.99
Upside: +27.51%
The Cooper Companies
Aug 28, 2025
Maintains: Overweight
Price Target: $105 → $83
Current: $69.69
Upside: +19.10%
Solventum
Aug 8, 2025
Maintains: Overweight
Price Target: $87 → $94
Current: $73.34
Upside: +28.18%
Becton, Dickinson and Company
Aug 8, 2025
Maintains: Neutral
Price Target: $185 → $200
Current: $193.30
Upside: +3.47%
Masimo
Aug 6, 2025
Maintains: Overweight
Price Target: $200 → $210
Current: $150.81
Upside: +39.25%
Envista Holdings
Aug 1, 2025
Maintains: Neutral
Price Target: $17 → $19
Current: $20.47
Upside: -7.18%
Merit Medical Systems
Jul 31, 2025
Maintains: Overweight
Price Target: $110 → $105
Current: $83.18
Upside: +26.23%
Align Technology
Jul 31, 2025
Maintains: Overweight
Price Target: $250 → $190
Current: $130.63
Upside: +45.45%
Pulmonx
Jul 31, 2025
Downgrades: Neutral
Price Target: $9 → $2.5
Current: $1.74
Upside: +43.68%
NovoCure
Jun 27, 2025
Reiterates: Overweight
Price Target: $34
Current: $14.25
Upside: +138.60%
May 8, 2025
Maintains: Neutral
Price Target: $4.5 → $3.5
Current: $4.00
Upside: -12.50%
Apr 30, 2025
Maintains: Neutral
Price Target: $20 → $16
Current: $12.45
Upside: +28.51%
Apr 30, 2025
Maintains: Overweight
Price Target: $83 → $77
Current: $65.77
Upside: +17.07%
Apr 23, 2025
Maintains: Neutral
Price Target: $15 → $13
Current: $16.15
Upside: -19.50%
Mar 28, 2025
Maintains: Overweight
Price Target: $5 → $4.5
Current: $2.22
Upside: +102.70%
Feb 3, 2025
Maintains: Overweight
Price Target: $260 → $265
Current: $242.84
Upside: +9.13%
Nov 7, 2024
Maintains: Overweight
Price Target: $8 → $6
Current: $4.70
Upside: +27.80%
Aug 15, 2024
Reiterates: Overweight
Price Target: $7
Current: $4.12
Upside: +69.90%
Aug 7, 2024
Maintains: Overweight
Price Target: $70 → $20
Current: $2.41
Upside: +729.88%
Jan 3, 2024
Maintains: Outperform
Price Target: $310 → $372
Current: $442.94
Upside: -16.02%
Apr 19, 2023
Initiates: Overweight
Price Target: $95
Current: $74.96
Upside: +26.73%